Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES (Tables)

v3.23.2
ACCRUED EXPENSES (Tables)
6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities [Table Text Block]

Accrued expenses consisted of the following:

 

 

 

June 30,
2023

 

 

December 31,
2022

 

 

 

 

 

 

 

 

Accrued pre-clinical and clinical costs

 

$

2,694,611

 

 

$

2,137,317

 

Accrued product development costs

 

 

758,699

 

 

 

247,500

 

Accrued compensation

 

 

1,570,376

 

 

 

2,224,951

 

Accrued administrative costs

 

 

282,846

 

 

 

473,376

 

Accrued interest

 

 

1,112,271

 

 

 

916,108

 

Total

 

$

6,418,803

 

 

$

5,999,252